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LETTER TO THE EDITOR 
We are plea&ed to receive Letters to the Editor on appropriate subjects. These Letters should be 
submitted in typewritten form, double-spaced, and are not to exceed 2 1'' pages. When appro-
priate, we wiD solicit commeJlts from the original authors. All Letters to the Editor are subject 
to editing and possible abridgment. 
To the Editor: 
I read with great interest the report entitled 
"Evaluation of atrophy production and vasocon· 
strictor potency in humans following intradermally 
injected corticosteroids" by Snyder and Greenberg 
(J Invest Dermatol 63:461-463, 1974). In their 
beautifully designed experiment the authors dem-
onstrated well that the vasoconstrictor effects of 
different corticosteroids and these compounds' 
ability to produce cutaneous atrophy are not neces-
sarily directly correlated. Since several investiga-
tors have reported a correlation between vasocon-
strictor potency and anti-inflammatory activity of 
corticosteroids, this finding suggests the possibility 
that certain corticosteroids such as desonide may 
be clinically effective but might be less likely than 
fluorinated compounds to cause atrophy of treated 
skin. 
In the discussion of their findings, the authors 
state that they "are aware of no direct comparison 
between triamcinolone acetonide and desonide for 
therapeutic efficacy.'· I would like to bring to their 
attention a paper read before the Section of Der-
matology of the Southern Medical Association in 
November, 1971, at Miami Beach, on the other 
side of Biscayne Bay (Smith EB, Gregory JF, 
Bartruff JK: Desonide, a potent non-fluorinated 
topical steroid, vasoconstriction assay and clinical 
trial. South Med J 66:325-329, 1973). My co-
workers and I compared the effect of desonide 
0.05% cream with that of triamcinolone aceto-
nide 0.1% cream in 84 patients with inflamma-
tory dermatoses in a double-blind controlled 
study. Our results demonstrate no significant dif-
ference between the two preparations. Using a 
relatively crude variation of the McKenzie-Stough-
ton vasoconstriction assay, we found desonide 
0.05% to be equivalent in vasoconstrictor potency 
to triamcinoline acetonide 0.1 %, fluocinolone 
0.025%, and flurandrenolone 0.05%. 
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Although final judgment on whether topical 
preparations of desonide will prove less likely to 
cause striae and atrophy must wait for more 
prolonged experience and observations. Snyder 
and Greenberg's work certainly suggests that this 
clinicallv effective non-fluorinated corticosteroid 
may be· relatively free of these troublesome side 
effects. 
Edgar B. Smith, M.D. 
Division of Dermatology 
University of New Mexico School of Medicine 
Albuquerque. New Mexico 
It must be emphasized that the study by Snyder 
and Greenberg dealt with chanfiles following intra-
dermal injection of several steroids. No data were 
reported which directly relate to topical applica-
tion. 
Editor 
